COMMUNIQUÉS West-GlobeNewswire

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
20/01/2026
VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
20/01/2026
Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to $5,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge [...]
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
20/01/2026
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and [...]
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
20/01/2026
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential approval of IGALMI ® [...]
BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
20/01/2026
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc ., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug [...]
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
20/01/2026
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter [...]
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
20/01/2026
Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026 Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage [...]
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
20/01/2026
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from [...]
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20/01/2026
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food [...]
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
20/01/2026
Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
20/01/2026
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations January 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124 [...]
Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
20/01/2026
Communiqué de presse Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques 20 janvier 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
19/01/2026
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19, 2026 – Valneva SE [...]
Valneva fait un point sur son vaccin contre le chikungunya IXCHIQ®
19/01/2026
La Société retire volontairement ses demandes d’autorisation de mise sur le marché (BLA) et d’essais cliniques (IND) aux États-Unis Et continue d’évaluer le potentiel mondial du produit en fonction des besoins médicaux [...]
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL
19/01/2026
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL Fleurieux-sur-l’Arbresle – France – 19 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce que sa [...]
Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis
19/01/2026
Consumer verification searches for Metabo Drops have intensified as "Is It Legit?" queries and ingredient transparency questions reshape how buyers evaluate liquid metabolism drops — this 2026 analysis examines safety [...]
GUERBET : Bilan semestriel du contrat de liquidité
19/01/2026
Bilan semestriel du contrat de liquidité Villepinte, le 19 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]
Virbac: solid 2025 dynamic with annual revenue up +7.9% at CERS3; with strong momentum in key categories and countries
19/01/2026
Full-year 2025 revenue reached €1,465m : +7.9% at constant exchange rate and scope (CERS) vs 2024 +4.8% at actual rates impacted by significant currency headwinds, particularly in Latin America, IMEA and the Pacific. [...]

Pages